Lavine Hemlani

Lavine Hemlani recommends keeping capital allocation, the story and decisions about key people, and outsourcing the rest.

• The same test applies to finance hires: a bookkeeper records what happened; a strategic CFO builds the milestone model and investor-ready data room that close a round.
• The suggested interview question: would this person build a burn-to-milestone model or just pull last month's actuals?
• They go further, arguing that the right engagement is not a fraction of a person but an operator embedded inside the company—a phrase borrowed from Palantir and heard from a founder who took a biotech public at a billion-dollar valuation.
• Hemlani's firm, Zenith, sells fractional CFO work to companies doing $1M to $50M+ in revenue; that is the service being described.

The handoff list includes grant applications and R&D tax credits, which they call free runway; CRO contract management, where audits they cite found $600K and $1.5M in single cases; FDA submission mechanics; and the data room, which should be built before the raise, not in a panic during it.

One post frames the problem as a mismatch between bookkeepers and CFOs; later posts broaden it into a rule about attention and a named engagement model: the forward-deployed operator.

Read original · Original 2 · Original 3 · Original 4

The advice: story is not leverage, traction is, because terms improve month by month.

• A second rule is to match the story to the source of the investor's wealth.
• Families that built fortunes in regional real estate, trade or manufacturing respond to a domestic-capability pitch; a foreign family office that merely keeps an office in Dubai needs a different one.
• The third rule reframes the competition: it is not other startups but local real estate and monopoly stocks such as the water company or the parking authority.
• If a deal cannot beat the water company, they say, do not take the meeting.
• Dubai and Abu Dhabi are treated as two different wallets: Dubai took almost all UAE tech funding in a quarter, while Abu Dhabi holds sovereign and industrial money.

A founder they describe watched a sovereign investor go from rejecting him as too early to wanting 30% of the company within months. He stalled; ninety days of revenue on the books would have produced the same conversation at triple the terms.

Read original · Original 2

The UAE, they write, can put every piece under one roof and move quickly, through Mubadala's holdings, with drug discovery now its largest investment sector; a Longevity Authority chaired at crown-prince level; new biopharma manufacturing campuses; and a national genomics program feeding drug development.

• They note that the West keeps the best scientists and that the UAE makes under 5% of the medicine it uses.
• The execution challenge is finding people who can turn a sovereign mandate into a company.
• A companion post contrasts the US, where venture dollars into biotech stayed near a record while biotech's share of US venture funding fell to just above 8% as AI absorbed more than half of it, with Gulf funds that have ring-fenced multi-billion-dollar life-science portfolios.

They cite Qatar's fund deploying over $9B into biotech in five years, Saudi's PIF ring-fencing a $4B life-sciences portfolio targeting a leading hub by 2040, and the UAE's $5B+ over five years, with plans to double it by 2030.

Read original · Original 2

They list the requirements: defending the science through months of diligence; understanding the full chain, from regulatory and clinical work to manufacturing and market access; access to the specific person inside a large pharma who needs the asset; structuring milestone-based deals rather than naming a price; and having personally closed deals.

• The structuring point carries the most weight: upfront cash is only about 7% of total deal value, with the rest paid over years and contingent on the science working.
• Their practical test for anyone offering to do business development: have you closed one of these, start to finish?

The framing figures are $270 billion flowing through biopharma partnerships in a single year and 65% of big pharma's newly approved drugs coming from biotech companies through deals.

Read original

Their counterargument is arithmetic: a tech-enabled service already trades at 13 to 18 times earnings, capturing most of the software upside without becoming a different kind of business.

• A companion argument, drawn from onboarding multi-entity supply chain customers, is that services are the source of the product, not its enemy.
• The messy manual work done for customer three becomes the playbook productized for customer thirty; the founder should onboard the first ten customers personally.

They describe a distributor employing one person full time to reconcile inventory across three warehouses in two different ERPs, and a CFO's brother emailing P&Ls to the family holding company every month in a ZIP file—the kind of workaround a demo never shows.

Read original · Original 2

Their answer is a system they call the 2nd Brain, built on a concept they credit to AI researcher Andrej Karpathy, in which the AI maintains the knowledge base. Add a meeting note, article or voice memo, and it writes a structured page and links it to what is already stored, so a conversation about a client's financial structure from months ago surfaces alongside a framework saved last week.

They describe noticing a pattern in someone's behaviour years earlier, then seeing it surface in a meeting the next day. The payoff, they say, is asking the system a question six months later and getting an answer drawn from everything you have saved.

Read original

They describe them as translators who speak hardware, software, logistics and market trends at once: they can take a sketch from a European designer, know what a factory needs to produce it, identify which component supplier can deliver same-day, and judge whether a market in Dubai will pay for it. Their conclusion: high-value businesses are built at the intersection of several fields, not at the centre of one.

They compare this to Steve Jobs, who, they say, did not build the iPhone by being the best engineer but by holding calligraphy, retail, psychology and technology at once.

Read original

The UAE is described as the world’s most active capital market, even though private venture capital is a small fraction of its sovereign wealth. The post distinguishes Dubai’s focus on startups and fintech from Abu Dhabi’s role as the seat of sovereign and industrial capital.

For brands planning a campaign

A venture fund targeting the UAE can use this to tailor its strategy to regional sovereign wealth funds and traditional private tech investors.

The UAE is unifying its biotech ecosystem, coordinating capital, regulation, manufacturing, and data under a central national drive. This contrasts with the fragmented model found in the West.

For brands planning a campaign

A pharma BD team can use this structural advantage to plan market entry, focusing on the country’s accelerated regulatory and manufacturing mandates.

Biotech business development (BD) requires more than a smooth sales pitch. Effective BD professionals must defend the underlying science, master the deal chain from regulatory hurdles to market access, and structure complex milestone-based payments.

For brands planning a campaign

Pharma BD teams can use these criteria to vet potential partners or internal teams, checking that their expertise spans the technical and financial demands of a major license.

As US venture capital faces challenges from the rise of AI, the Gulf is building its life-sciences industry, with nations like Saudi Arabia and the UAE targeting a massive regional ecosystem.

For brands planning a campaign

A biotech fund should treat the Gulf as a primary, coordinated growth market for life sciences, not a secondary investment option.

Success when pitching to Gulf sovereign wealth depends on using traction—not just narrative—as leverage. Tailor pitches to the source of the wealth (e.g., real estate, trade, manufacturing).

For brands planning a campaign

Companies seeking Gulf investment should research each investor’s regional economic focus and tailor their company narrative accordingly.

Founders need more than consultants; they need a 'forward-deployed operator' embedded in the company to build financial infrastructure, such as a data room or investment model, and prepare for funding milestones.

For brands planning a campaign

Investors or strategic partners can use this model to hire embedded operational experts who help de-risk a target company’s path to public markets.

Distinguish between a bookkeeper, who records history, and a strategic CFO, who builds investor-ready growth narratives and financial models tied to future milestones.

For brands planning a campaign

Financial partners or advisory boards can use this distinction to vet service providers and ensure the engagement adds strategic value beyond clerical tasks.

For multi-entity businesses, including those in supply chains, effective scaling starts with hands-on customer onboarding. Understanding the manual, messy work in a customer's environment lays the foundation for scalable software.

For brands planning a campaign

Tech-enabled service providers and SaaS startups can use this insight to refine their sales cycles and prioritize deep customer immersion over immediate product automation.

Zenith provides fractional CFO services to founders and CEOs of multi-entity businesses in SaaS, e-commerce, and professional services who need high-level financial oversight without a full-time executive hire.

For brands planning a campaign

This presents a market opportunity for financial services firms looking to partner with scale-up founders.

Business leaders often mistake turning a profitable service business into SaaS as the only path to value. But successful tech-enabled services already command high multiples (13x-18x earnings), making the transition a costly, often unnecessary risk.

For brands planning a campaign

Advisors can help businesses choose a scaling path, including a high-multiple service model instead of a resource-intensive software build.

Accumulated business judgment—the patterns, mistakes, and insights gained over years of experience—is an executive's most critical, yet least accessible, asset. Technology such as an LLM Wiki can help capture and use that judgment.

For brands planning a campaign

Consulting firms can help leaders put their institutional knowledge to work through specialized knowledge management tools.

Shenzhen's rapid development is driven by its workforce of 'translators'—people working across domains such as hardware, software, logistics, and market trends. Success comes from synthesizing knowledge across fields.

For brands planning a campaign

Investors should look for founding teams or partners with multidisciplinary, intersectional fluency, not just domain-specific expertise.

The UAE and regional entities are deploying significant funds, making the region a critical market for life sciences and advanced manufacturing. But capital and investment rules vary widely between financial hubs such as Dubai and industrial centers such as Abu Dhabi.

For brands planning a campaign

For marketers targeting audiences interested in the GCC growth story, sovereign wealth funds, or how to pitch to regional capital pools, from local families to sovereign entities.

Examples: Source 1 · Source 2 · Source 3

Unlike the fragmented Western approach, this centralized structure allows for rapid deployment and strategic market dominance in life sciences.

For brands planning a campaign

For pharmaceutical companies and biotech startups exploring UAE market entry, particularly those focused on centralized drug discovery and regulatory speed.

Examples: Source 1

Success requires people who can defend the science, understand the full value chain from science to market access, and structure complex, milestone-based licensing deals—not just upfront sales.

For brands planning a campaign

For life sciences firms seeking to sharpen their BD strategy, improve partnership negotiations, or hire operators who can defend complex scientific assets during due diligence.

Examples: Source 1

Effective solutions require “white-glove” engagement: working with customers to understand the messy, manual processes they use. This embedded observation provides the “source code” for product design and sustainable scaling.

For brands planning a campaign

For B2B software and SaaS vendors, consulting firms, and internal innovation teams refining product roadmaps and service delivery around clients’ operational realities.

Examples: Source 1

Founders need a “forward-deployed operator” embedded in the company, owning its financial and operational machinery and delivering tangible outcomes—such as a completed data room or a successful raise—rather than just offering advice.

For brands planning a campaign

For organizations seeking fractional CFO or operational support with deep, hands-on integration—not surface-level consultation or bookkeeping.

Examples: Source 1

A bookkeeper, by contrast, records and reports past transactions.

For brands planning a campaign

For founders and executives seeking to move financial management beyond transactional record-keeping toward strategic, growth-oriented financial engineering.

Examples: Source 1 · Source 2

AI-based “LLM Wikis” and “2nd Brain” systems can help founders and executives structure and use this institutional knowledge.

For brands planning a campaign

For thought leaders, executive search firms, and productivity or AI tools targeting senior decision-makers who want to synthesize their professional histories and accumulated insights.

Examples: Source 1

The ability to bridge these fields as a “translator” helps solve complex manufacturing and market-entry challenges.

For brands planning a campaign

For firms in complex physical or tech-enabled industries, and those seeking leaders who can synthesize diverse skill sets to create new commercial opportunities.

Examples: Source 1

Business leaders must also decide whether to grow a highly profitable service business or convert it into a software model, weighing the risks and different valuation multiples.

For brands planning a campaign

For services brands, e-commerce retailers, and VCs seeking clear guidance on business model choices and financial health indicators for mid-market growth.

Examples: Source 1 · Source 2

The posts do not state Lavine Hemlani’s ownership or employment relationship with the business.

View example

View example

Dan Lewis tracks licensing deals and company moves, including a $15.2B oncology and immunology licensing deal and a drug becoming the world's top seller.

• He also covers life-sciences manufacturing, including digital manufacturing, automation and CQV work after an acquisition.
• Lavine Hemlani covers the same territory from another angle, explaining what makes a biopharma deal close and treating manufacturing as part of a national biotech build-out.
• Both publish short, numbered LinkedIn posts that lead with a figure or deal.

Dan Lewis reports and summarises events across the industry, giving readers a digest of what happened and why it matters.

• Lavine Hemlani argues a position and offers founders operating advice, framing it around Gulf capital and how to run a life-science company.
• Readers looking for a steady industry news feed would follow Lewis; those seeking a point of view on how to act on that news would follow Hemlani.

Read original · Original 2

Ghazi Benothman uses AI adoption data to compare Tunisia with the UAE and Qatar.

• He also runs a small-ticket programme backing first-time Tunisian and diaspora founders in deep tech, explicitly including life sciences alongside cybersecurity, AI, semiconductors, quantum, drones and robotics.
• Lavine Hemlani makes a similar case using Gulf figures, weighing sovereign and family money against venture funds and advising founders on which room to pitch in.

Ghazi Benothman focuses on Tunisia and its diaspora at the earliest stage, with small safe-note cheques and an investment programme he promotes in his posts. Lavine Hemlani writes about Gulf sovereign and family capital, and about the finance and business-development work that comes later, when a company has traction to defend in a negotiation.

Read original · Original 2

Matthew Holt explains why procurement is often brought in after the specification is locked, leaving only the margin on a decision someone else made to negotiate.

• He offers concrete advice for supplier meetings, including asking how a counterparty actually chooses between suppliers and following up within 48 hours.
• Lavine Hemlani applies a similar approach to business development: upfront cash is a small share of a deal, so the test is whether someone has closed one from start to finish.

Matthew Holt focuses on procurement and supplier partnerships, and offers a sourcing consultancy for pharmaceutical and biotech companies.

• Lavine Hemlani focuses on founder finance, licensing deals and regional capital, and offers fractional and embedded CFO work alongside commentary on Gulf investment.
• Their overlap is less about subject matter than method: applying a practical test to a relationship.

Read original · Original 2

One post is a dated roundup of industry events: a $15.2B Bristol Myers Squibb licensing deal with Jiangsu Hengrui across 13 early-stage programs, FDA leadership departures, Takeda's plan to cut 4,500 jobs by March 2027, Eli Lilly's Mounjaro becoming the top-selling drug in Q1 2026 at $8.7B, Daiichi Sankyo's oncology targets, the EU's provisional Critical Medicines Act covering about 270 drugs, and Isomorphic Labs raising $2.1B for AI drug design.

• The other explains the completed acquisition of SimoTech by Project Farma and PerkinElmer, arguing that digital manufacturing, automation, CQV and operational readiness should be aligned across the facility lifecycle rather than fixed one discipline at a time.
• For a fund tracking licensing activity or backing a company building a biotech facility, that material is closer to day-to-day decisions than a Gulf capital briefing.

Neither post discusses Gulf sovereign money, family offices or regional venture capital, so Dan Lewis cannot ground a UAE market-entry plan in how capital behaves there.

• Their focus is pharma industry news and manufacturing and CQV project delivery—not which Gulf investors a founder should approach or what evidence they expect.
• Bring them in for deal-flow tracking and facility execution; ask a separate regional adviser for the capital thesis.

Examples: Source 1 · Source 2

In one post, they describe a small-ticket programme writing €50,000 SAFE notes to first-time founders from Tunisia and the diaspora.

• It is limited to deep tech—life sciences, cybersecurity, B2B AI, semiconductors, quantum, drones and robotics—with fintech, mobility and local hobby projects explicitly excluded; pitches are reviewed with a named partner at MEDIN.
• The other post interprets the Anthropic Economic Index for Tunisia, arguing that the country uses AI as a production tool rather than a consumption one, and points to software development, math and computer-science theory, and devops work as distinctive categories.
• For a fund seeking North African or diaspora deep-tech founders at demo stage and beyond, that is the lane they describe.

The instrument described is a €50,000 SAFE note at pre-seed.

• The posts do not cover UAE sovereign wealth, family offices or regional manufacturing mandates.
• They widen founder access but do not address which Gulf investors a portfolio company should pitch, how Dubai and Abu Dhabi divide, or how to structure a milestone-heavy pharma deal.
• Use them to source companies; ask a regional adviser for the market-entry argument.

Examples: Source 1 · Source 2

As co-founder of Collaborative Sourcing, a procurement consultancy for life-science industries, they argue that procurement is usually brought in late because organisations have already decided its role is to get a better price on a chosen supplier.

• By then, most available value is fixed, and procurement is judged on savings against a baseline it did not set.
• Their CPHI advice is specific and portable: arrive with two or three questions you genuinely need answered, ask how the other side actually chooses between suppliers rather than what they need, follow up within 48 hours referencing something exact they said, and resist overselling in the room.

Their focus is purchasing and supplier relationships, not capital or market entry.

• The posts offer no Gulf investment analysis or fundraising and licensing-structure advice.
• They could help a portfolio company negotiate with suppliers and improve its approach to short partnering meetings, but not identify which Gulf investors to pitch or how to price an upfront-versus-milestone deal.
• Ask a regional adviser for that strategy.

Examples: Source 1 · Source 2